Abstract |
In the EORTC lymphoma cooperative group, a randomized phase III study was done for patients with stage II, III, IV intermediate- and high-grade lymphoma. Eight courses of CHVmP-VB were compared to eight courses of ProMACE-MOPP. Response was evaluated after 8 courses. Of 430 patients entered, 346 were eligible for this first analysis. Additional radiotherapy was given at initial large masses or residual disease after three courses. Response rate was higher in the CHVmP-VB arm in comparison to the ProMACE-MOPP arm, 82% vs. 65% (p < 0.0005). In the ProMACE-MOPP arm, treatment had to be interrupted because of patient refusal in 7% of the patients. So far there has been no significant difference in freedom from progression at 5 years (49% vs. 47%), relapse-free survival (59% vs. 59%), or overall survival (55% vs. 49%). Patients with early response at 4 courses showed no better RFS in comparison with late responders between 4 and 8 courses. The International Index, based on age, stage, SLDH, performance status, and number of extranodal localizations showed a good prognostic significance in this series of patients.
|
Authors | R Somers, P Carde, J Thomas, U Tirelli, J J Keuning, D Bron, A Delmer, R de Bock, C De Wolf-Peeters, J J Keunig |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 5 Suppl 2
Pg. 85-9
( 1994)
ISSN: 0923-7534 [Print] England |
PMID | 7515651
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Bleomycin
- Procarbazine
- Mechlorethamine
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Teniposide
- Leucovorin
- Prednisone
- Methotrexate
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Bleomycin
(administration & dosage, adverse effects)
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage, adverse effects)
- Doxorubicin
(administration & dosage, adverse effects)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Leucovorin
(administration & dosage, adverse effects)
- Life Tables
- Lymphoma, Non-Hodgkin
(drug therapy, mortality, pathology, radiotherapy)
- Male
- Mechlorethamine
(administration & dosage, adverse effects)
- Methotrexate
(administration & dosage, adverse effects)
- Middle Aged
- Neoplasm Staging
- Prednisone
(administration & dosage, adverse effects)
- Procarbazine
(administration & dosage, adverse effects)
- Remission Induction
- Survival Analysis
- Teniposide
(administration & dosage, adverse effects)
- Thrombocytopenia
(chemically induced)
- Treatment Outcome
- Vincristine
(administration & dosage, adverse effects)
|